NE HEALTH BUREAU
MUMBAI, MAY 22
In a significant advancement for India’s pharmaceutical industry and affordable global healthcare access, Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Levothyroxine Sodium Tablets USP used in the treatment of thyroid-related disorders.
The approval marks another major milestone in Alembic’s expanding global generics portfolio and further strengthens India’s role as a leading supplier of affordable and high-quality medicines to regulated international markets.
- Alembic Pharmaceuticals Limited receives final USFDA approval for Levothyroxine Sodium Tablets across multiple dosage strengths
- Thyroid treatment drug has an estimated US market size of nearly $1.87 billion, according to IQVIA
- Approval boosts Alembic’s growing portfolio of regulated market products with total USFDA ANDA approvals reaching 239
- Development expected to strengthen access to affordable treatment for hypothyroidism and thyroid-related disorders globally
Big Boost in Thyroid Care Segment
The approved medication is therapeutically equivalent to Synthroid tablets manufactured by AbbVie.
Levothyroxine Sodium Tablets are widely prescribed for:
- Hypothyroidism treatment
- Thyroid hormone replacement therapy
- Congenital thyroid disorders
- Pituitary and hypothalamic thyroid deficiencies
- Thyroid cancer management support
Medical experts say thyroid disorders continue to rise globally due to lifestyle changes, stress, hormonal imbalance and metabolic conditions, making affordable treatment options increasingly important.
Entry into a Multi-Billion Dollar Market
According to IQVIA estimates, the approved product segment recorded a market size of nearly US$ 1.869 billion for the twelve months ending March 2026.
Industry analysts believe the approval places Alembic in a strategically important and highly competitive therapeutic category within the US generics market.
The company has received approval for multiple strengths of the medication, including:
- 25 mcg
- 50 mcg
- 75 mcg
- 88 mcg
- 100 mcg
- 112 mcg
- 125 mcg
- 137 mcg
- 150 mcg
- 175 mcg
- 200 mcg
- 300 mcg
Strengthening India’s Pharma Innovation Story
The latest approval also reflects the growing capability of Indian pharmaceutical companies in meeting stringent global regulatory standards.
With this development, Alembic now has:
- 220 final ANDA approvals
- 19 tentative approvals
- Total cumulative approvals reaching 239 from USFDA
Healthcare industry observers said the approval reinforces India’s position as a global hub for affordable generic medicines and pharmaceutical manufacturing excellence.
Expanding Affordable Global Healthcare Access
The approval is expected to enhance availability of cost-effective thyroid medications for patients in the United States and other international markets.
Experts noted that increasing competition in the generic drug market can significantly improve:
- Patient affordability
- Medicine accessibility
- Healthcare sustainability
- Long-term treatment adherence
The development is also being viewed as a positive signal for India’s pharmaceutical export ecosystem amid rising global demand for affordable chronic disease therapies.
